Epic Test Code DMNES Peripheral Nervous System Demyelinating Neuropathy, Autoimmune Evaluation, Serum
Ordering Guidance
Multiple neurological phenotype-specific autoimmune/paraneoplastic evaluations are available. For more information as well as phenotype-specific testing options, refer to Autoimmune Neurology Test Ordering Guide.
For a list of antibodies performed with each evaluation, see Autoimmune Neurology Antibody Matrix.
Specimen Required
Patient Preparation: For optimal antibody detection, specimen collection is recommended to occur prior to initiation of immunosuppressant medication or intravenous immunoglobulin treatment.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 3 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Forms
If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.
Useful For
Evaluating patients with a suspected immune-mediated demyelinating peripheral neuropathy
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
DMNI | Demyelinating Neuropathy Interp, S | No | Yes |
CONCS | Contactin-1 IgG CBA, S | No | Yes |
GQ1ES | GQ1b-IgG ELISA, S | Yes | Yes |
IGG_D | IgG Disialo. GD1b | No | Yes |
IGM_D | IgM Disialo. GD1b | No | Yes |
IGG_M | IgG Monos. GM1 | No | Yes |
IGM_M | IgM Monos. GM1 | No | Yes |
MAGES | MAG IgM, S | Yes | Yes |
NF4FS | Neurofascin-155 IgG4, S | No | Yes |
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
IGDTS | IgG Disialo GD1b Titer, S | No | No |
IMDTS | IgM Disialo GD1b Titer, S | No | No |
IGMTS | IgG Monos GM1 Titer, S | No | No |
IMMTS | IgM Monos GM1 Titer, S | No | No |
Testing Algorithm
Screening tests are performed for IgG and IgM antibodies to GM1 and GD1b. If positive, the appropriate titer will be performed at an additional charge.
For more information see:
Method Name
DMNI: Technical Interpretation
CONCS: Cell-Binding Assay (CBA)
GQ1ES, IGG_D, IGM_D, IGG_M, IGM_M, IGDTS, IMDTS, IGMTS, IMMTS, MAGES: Enzyme-Linked Immunosorbent Assay (ELISA)
NF4FS: Flow Cytometry
Reporting Name
Demyelinating Neuropathy Ab Eval, SSpecimen Type
SerumSpecimen Minimum Volume
2 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 72 hours |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Clinical Information
Immune-mediated neuropathies refer to a group of disorders that share overlapping sensory, motor, and autonomic clinical, laboratory, and electrodiagnostic features. Testing for autoantibodies associated with immune-mediated neuropathies should be considered after a detailed history and physical examination is completed. In most situations, nerve conduction studies and electromyography are crucial in distinguishing between primary axonal, primary demyelinating, or mixed axonal and demyelinating neuropathies. This enables a more focused testing approach for disease-relevant autoantibodies. This evaluation focuses on persons with immune-mediated demyelinating neuropathies.
The antibody tests included in this evaluation aim to support the diagnosis of an immune-mediated demyelinating neuropathy as well aid in distinguishing between the more common forms of immune-mediated demyelinating neuropathies that are associated with sensitive and specific antibody biomarkers.
Autoantibodies directed against myelin-associated glycoprotein are associated with sensory motor demyelinating peripheral neuropathy. A distal acquired demyelinating symmetric (DADS) neuropathy phenotype is the most commonly-associated presentation. This may mimic distal forms of chronic inflammatory demyelinating polyneuropathy (CIDP). Patients typically have a slowly progressive symmetric sensory ataxia with or without distal weakness and an IgM monoclonal gammopathy of undetermined significance. Nerve conduction studies typically demonstrate a characteristic progressive sensory-predominant mixed axonal and demyelinating neuropathy with reduced distal conduction velocities that are greater distally. In general, patients with a DADS neuropathy show limited treatment responses to intravenous immunoglobulin (IVIG), and more aggressive immunotherapy may be needed.
A subset of patients with suspected CIDP have been identified with autoantibodies targeting nodal-paranodal proteins. These patients share common immunopathological mechanisms of disease, clinical features, and treatment responses that are distinct from classic CIDP. A common target of these autoantibodies is the neurofascin-155 (NF155)-contactin-1 (CNTN1) adhesion complex, which is critical in maintaining the paranodal myelin-axon junction. NF155 is expressed at the paranodal loops of Schwann cells where it interacts with CNTN1 expressed on adjacent axons. This interaction stabilizes and allows the proper organization of the paranodal axoglial junction. Antibody-mediated disruption of this interaction in animal models recapitulates the pathophysiology observed in humans.
NF155 IgG antibodies are present in approximately 5% to 10% of patients with CIDP-like presentations and, more rarely, in those with more acute forms of demyelinating polyradiculoneuropathy. NF155 IgG positive cases are more likely to present with distal weakness, gait disturbance, tremor, and dysarthria as compared to classic CIDP. Most patients who are seropositive for NF155 IgG have been reported to be refractory to IVIG therapy and often require second-line treatment that includes B-cell depleting therapies, such as rituximab. The detection of NF155 IgG4 is a highly-specific finding and has not been reported in other disease mimics, such as hereditary neuropathies, distal acquired demyelinating symmetric neuropathy, and motor neuron disease.
CNTN1 IgG antibodies are present in approximately 2% of patients with CIDP-like presentations. CNTN1 IgG-positive cases are more likely to present with neuropathic pain, sensory ataxia, and subacute progressive demyelinating polyradiculoneuropathy or polyradiculopathy. The majority of seropositive patients have been reported to be refractory to treatment with IVIG. However, some of these patients respond well to B-cell depleting therapies, such as rituximab. Up to half of CNTN1 IgG-positive patients with CIDP or CIDP-like presentations have been reported to develop membranous nephropathy, and thus, screening for proteinuria may be warranted.
Autoantibodies targeting ganglioside GQ1b are associated with a group of disorders that includes Miller Fisher syndrome (MFS), Bickerstaff brainstem encephalitis (BBE), and classic Guillain-Barre syndrome (GBS) with ophthalmoplegia. Collectively these are referred to as GQ1b IgG-related syndromes, which reflects the diverse clinical presentations associated with these autoantibodies. The prevalence of GQ1b IgG in MFS and BBE is high and has been reported to be greater than 80% in well-defined clinical cohorts. GQ1b IgG may occur in patients with GBS but generally with a lower prevalence.
Autoantibodies targeting ganglioside GD1b antibodies frequently occur in sensory ataxic conditions such as chronic, ataxic, neuropathy, ophthalmoplegia, IgM gammopathy, cold agglutinins, and disialosyl antibodies (CANOMAD), acute sensory ataxic neuropathy (ASAN), and chronic ataxic neuropathy with disialosyl antibodies (CANDA).
Autoantibodies targeting ganglioside GM1 more commonly occur in patients with multifocal motor neuropathy (MMN), multifocal acquired demyelinating sensory and motor (MADSAM) neuropathy, and motor-predominant Guillain-Barre syndrome.
Reference Values
Contactin-1 IgG CBA: Negative
GQ1b-IgG ELISA: Negative
IgG Disialo. GD1b: Negative
IgM Disialo. GD1b: Negative
IgG Monos. GM1: Negative
IgM Monos. GM1: Negative
MAG IgM: <1500 Buhlmann titer unit
Neurofascin-155 IgG4: Negative
Reflex Information:
IgG Disialo GD1b Titer: <1:2000
IgM Disialo GD1b Titer: <1:2000
IgG Monos GD1b Titer: <1:2000
IgM Monos GD1b Titer: <1:4000
Interpretation
The presence of specific autoantibodies or combinations of antibodies in this panel provides supportive evidence of an immune-mediated demyelinating peripheral neuropathy. However, these results must be interpretated in the appropriate clinical context. A negative result does not exclude the possibility of an immune-mediated demyelinating peripheral neuropathy.
Cautions
Negative results do not exclude a diagnosis of an immune-mediated demyelinating neuropathy. Autoantibody results should always be correlated with the clinical phenotype.
The use of immunotherapy prior to sample collection may result in either false-positive or false-negative results.
Day(s) Performed
Monday through Sunday
Report Available
5 to 8 daysSpecimen Retention Time
28 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterCPT Code Information
83516 x5
83520
86255 x2
83520 x4 (if applicable)